The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...

A researcher at the Wintrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences received a ...

Cancer cells have an insatiable appetite for energy as they multiply more rapidly than normal cells. Greedy cancer cells ...

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

A new paper in the Journal of Breast Imaging, published by Oxford University Press, indicates that breast cancer mortality rates have stopped declining in women older than age 74, and reconfirms that ...

An unassuming painkiller that most people have in their cupboard could help prevent the spread of cancer. Experts might have ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...